Orser Capital Management LLC Acquires Shares of 27,953 Edwards Lifesciences Corporation $EW

Orser Capital Management LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 27,953 shares of the medical research company’s stock, valued at approximately $2,174,000. Edwards Lifesciences makes up approximately 1.2% of Orser Capital Management LLC’s portfolio, making the stock its 25th biggest position.

Several other institutional investors and hedge funds have also recently modified their holdings of EW. Brighton Jones LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $266,000. Aptus Capital Advisors LLC boosted its stake in shares of Edwards Lifesciences by 3.8% in the first quarter. Aptus Capital Advisors LLC now owns 10,386 shares of the medical research company’s stock worth $753,000 after acquiring an additional 385 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. Banco Bilbao Vizcaya Argentaria S.A. raised its stake in Edwards Lifesciences by 21.8% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 182,269 shares of the medical research company’s stock valued at $13,214,000 after purchasing an additional 32,673 shares during the last quarter. Finally, Erste Asset Management GmbH lifted its holdings in Edwards Lifesciences by 1.7% in the 1st quarter. Erste Asset Management GmbH now owns 19,820 shares of the medical research company’s stock valued at $1,405,000 after purchasing an additional 326 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on EW shares. The Goldman Sachs Group set a $104.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday, October 31st. Citigroup restated a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Evercore ISI increased their price target on Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a report on Friday, October 31st. UBS Group set a $92.00 price objective on Edwards Lifesciences in a research report on Friday, December 5th. Finally, Robert W. Baird set a $87.00 price objective on Edwards Lifesciences and gave the stock a “neutral” rating in a research note on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.32.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 45,465 shares of company stock worth $3,804,610 over the last three months. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $84.85 on Thursday. The stock has a market capitalization of $49.24 billion, a price-to-earnings ratio of 36.58, a price-to-earnings-growth ratio of 3.84 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The business has a 50-day moving average of $82.10 and a 200 day moving average of $79.18. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business earned $0.67 EPS. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.